Civica Rx and Xellia Pharmaceuticals have signed a product supply agreement under which Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civica’s member health systems. Shortages of these anti-infective medications are impacting patient care in hospitals across the U.S.
 
The deal marks the first time that Civica is announcing the production of generic drugs—and the initial medications to be supplied—since the company was established to address chronic drug shortages. It has committed to partnering with suppliers to deliver 14 essential generic medications this year.
 
Xellia, headquartered in Copenhagen, Denmark, is expanding its manufacturing and sales capabilities within the U.S. The company produces its own active pharmaceutical ingredients, as well as finished injectable drug products for serious and often life-threatening bacterial and fungal infections.
 
“We thank Xellia for helping to lead the way in efforts to reduce chronic generic drug shortages in the U.S., including treatments for serious infections caused by bacteria that are resistant to other antibiotics,” said Martin VanTrieste, president and chief executive officer, Civica. “By helping to stabilize the supply of Vancomycin and Daptomycin, we will have a direct impact on patient safety and public health by providing consistent access to antibiotics that are important treatment options in the management of difficult-to-treat and life-threatening infections.”
 
The partnership with Xellia will help avoid drug shortages and enable the supply security Civica and its member health systems are seeking. Xellia will make medications for Civica under Xellia’s Abbreviated New Drug Application (ANDA) and Civica labeling and New Drug Code (NDC).
 
“We are honored to work with Civica, an innovator in addressing generic drug shortages,” said Carl-Aake Carlsson, chief executive officer, Xellia Pharmaceuticals. “Our collaboration also supports Xellia’s long-term ambition of mitigating anti-infective drug shortages across the U.S.”